Spectrum of activity, mutation rates, synergistic interactions, and the effects of pH and serum proteins for fusidic acid (CEM-102)

Diagnostic Microbiology and Infectious Disease

Volumn 66, Issue 3, 2010, Pages 301-307

  Biedenbach, Douglas J ^a   Rhomberg, Paul R ^a   Mendes, Rodrigo E ^a   Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CEM 102; Fusidic acid; Gram positive activity; S. aureus; Synergy

Indexed keywords

AZTREONAM; BACTERIAL PROTEIN; CEFTRIAXONE; CEM 102; CIPROFLOXACIN; FUSIDIC ACID; GENTAMICIN; LEVOFLOXACIN; OXACILLIN; RIFAMPICIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL MUTATION; BACTERIAL STRAIN; CONTROLLED STUDY; CORYNEBACTERIUM; DILUTION; DRUG ANTAGONISM; DRUG POTENCY; DRUG POTENTIATION; EMPEDOBACTER BREVIS; ENTEROCOCCUS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; MICROCOCCUS LUTEUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NEISSERIA MENINGITIDIS; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS;

ANTI-INFECTIVE AGENTS; BLOOD PROTEINS; CULTURE MEDIA; DRUG SYNERGISM; FUSIDIC ACID; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; HYDROGEN-ION CONCENTRATION; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MUTATION;

EID: 77349102026     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.10.014     Document Type: Article

References (28)

1. Anderson J.D. Fusidic acid: new opportunities with an old antibiotic. Can. Med. Assoc. J. 1980, 122:765-769.
2. Clinical and Laboratory Standards Institute (CLSI) Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard-seventh edition, M11-A7 2008, CLSI, Wayne, PA.
3. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-eighth edition, M07-A8 2009, CLSI, Wayne, PA.
4. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: 19th informational supplement (M100-S19) 2009, CLSI, Wayne, PA.
5. Collignon P., Turnidge J. Fusidic acid in vitro activity. Int. J. Antimicrob. Agents 1999, 12(Suppl. 2):S45-S58.
6. Corey G.R. Staphylococcus aureus bloodstream infections: definitions and treatment. Clin. Infect. Dis. 2009, 48(Suppl. 4):S254-S259.
7. Cornaglia G., Rossolini G.M. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens. Clin. Microbiol. Infect. 2009, 15:218-223.
8. Deresinski S. Counterpoint: Vancomycin and Staphylococcus aureus-an antibiotic enters obsolescence. Clin Infect Dis 2007, 44:1543-1548.
9. Deresinski S. Vancomycin heteroresistance and methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 2009, 199:605-609.
10. Hidayat L.K., Hsu D.I., Quist R., Shriner K.A., Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. 2006, 166:2138-2144.
11. Howden B.P., Grayson M.L. Dumb and dumber-the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin. Infect. Dis. 2006, 42:394-400.
12. Howden B.P., Ward P.B., Charles P.G., Korman T.M., Fuller A., du Cros P., Grabsch E.A., Roberts S.A., Robson J., Read K., Bak N., Hurley J., Johnson P.D., Morris A.J., Mayall B.C., Grayson M.L. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 2004, 38:521-528.
13. Kainer M.A., Devasia R.A., Jones T.F., Simmons B.P., Melton K., Chow S., Broyles J., Moore K.L., Craig A.S., Schaffner W. Response to emerging infection leading to outbreak of linezolid-resistant enterococci. Emerg. Infect. Dis. 2007, 13:1024-1030.
14. Lannergard J., Norstrom T., Hughes D. Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 2009, 53:2059-2065.
15. Larsen A.R., Skov R.L., Jarlier V., Henriksen A.S. Epidemiological differences between the UK and Ireland versus France in Staphylococcus aureus isolates resistant to fusidic acid from community-acquired skin and soft tissue infections. J. Antimicrob. Chemother. 2008, 61:589-594.
16. Laurent F., Tristan A., Croze M., Bes M., Meugnier H., Lina G., Vandenesch F., Etienne J. Presence of the epidemic European fusidic acid-resistant impetigo clone (EEFIC) of Staphylococcus aureus in France. J. Antimicrob. Chemother. 2009, 63:420-421.
17. Lewis J.S., Owens A., Cadena J., Sabol K., Patterson J.E., Jorgensen J.H. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob. Agents Chemother. 2005, 49:1664-1665.
18. Lode H.M. Clinical impact of antibiotic-resistant Gram-positive pathogens. Clin. Microbiol. Infect. 2009, 15:212-217.
19. Mason B.W., Howard A.J., Magee J.T. Fusidic acid resistance in community isolates of methicillin-susceptible Staphylococcus aureus and fusidic acid prescribing. J. Antimicrob. Chemother. 2003, 51:1033-1036.
20. McLaws F., Chopra I., O'Neill A.J. High prevalence of resistance to fusidic acid in clinical isolates of Staphylococcus epidermidis. J. Antimicrob. Chemother. 2008, 61:1040-1043.
21. Mendes R.E., Deshpande L.M., Castanheira M., DiPersio J., Saubolle M.A., Jones R.N. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob. Agents Chemother. 2008, 52:2244-2246.
22. O'Neill A.J., Larsen A.R., Skov R., Henriksen A.S., Chopra I. Characterization of the epidemic European fusidic acid-resistant impetigo clone of Staphylococcus aureus. J. Clin. Microbiol. 2007, 45:1505-1510.
23. Rennie R.P. Susceptibility of Staphylococcus aureus to fusidic acid: Canadian data. J. Cutan. Med. Surg. 2006, 10:277-280.
24. Skiest D.J. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J. Clin. Microbiol. 2006, 44:655-656.
25. Stryjewski M.E., Chambers H.F. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 2008, 46(Suppl. 5):S368-S377.
26. Tenover F.C., Moellering R.C. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis. 2007, 44:1208-1215.
27. Toh S.M., Xiong L., Arias C.A., Villegas M.V., Lolans K., Quinn J., Mankin A.S. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol. Microbiol. 2007, 64:1506-1514.
28. Tveten Y., Jenkins A., Kristiansen B.E. A fusidic acid-resistant clone of Staphylococcus aureus associated with impetigo bullosa is spreading in Norway. J. Antimicrob. Chemother. 2002, 50:873-876.